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Summary statement: 
We show that, in vivo, the Sox2 transcription factor is a potent inhibitor of Schwann 
cell myelination, promoting both Schwann cell proliferation and macrophage 
infiltration in peripheral nerve. 
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Abstract 
 
Correct myelination is crucial for the function of the peripheral nervous system. Both 
positive and negative regulators within the axon and Schwann cell function to ensure 
the correct onset and progression of myelination during both development and 
following peripheral nerve injury and repair. The Sox2 transcription factor is well 
known for its roles in the development and maintenance of progenitor and stem cell 
populations, but has also been proposed in vitro as a negative regulator of 
myelination in Schwann cells. We wished to test fully whether Sox2 regulates 
myelination in vivo and show here that sustained Sox2 expression in vivo blocks 
myelination in the peripheral nerves and maintains Schwann cells in a proliferative 
non-differentiated state, associated also with increased inflammation within the nerve. 
The plasticity of Schwann cells allows them to re-myelinate regenerated axons 
following injury and we show that re-myelination is also blocked by Sox2 expression 
in Schwann cells. These findings identify Sox2 as a physiological regulator of 
Schwann cell myelination in vivo and its potential to play a role in disorders of 
myelination in the peripheral nervous system. 
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Introduction 
Schwann cells (SC) are the myelinating glia of the peripheral nervous system (PNS), 
they myelinate large diameter axons and provide trophic support for both motor and 
sensory axons. The transcriptional programmes driving both myelination and the 
dedifferentiation of SCs following injury have been partially characterised and many 
positive regulators such as Krox20 (Egr2), Oct6 (SCIP or Tst1), Sox10 and NFATc4 
have been identified by both in vitro and in vivo analysis. However there is still little 
data on potential negative regulators of myelination in vivo that play roles in both the 
correctly timed onset of myelination and possibly in the pathology of demyelinating 
neuropathies of the PNS (Topilko et al., 1994, Svaren and Meijer, 2008, Jaegle et al., 
1996, Finzsch et al., 2010, Kao et al., 2009, Jessen and Mirsky, 2008).  
While the transcription factors Pax3, cJun and Sox2, activation of the Notch pathway, 
as well as signalling through the ERK1/2 and p38 mitogen activated protein (MAP) 
kinases, have been shown to inhibit myelination of SCs in vitro, there is only direct 
genetic evidence for Notch signalling, ERK1/2 and p38 activation regulating these 
processes in vivo (Yang et al., 2012, Le et al., 2005b, Parkinson et al., 2008b, 
Harrisingh et al., 2004b, Woodhoo et al., 2009b, Doddrell et al., 2012, Jessen and 
Mirsky, 2008, Napoli et al., 2012, Ishii et al., 2016, Ishii et al., 2013, Roberts et al., 
2016).  
The high mobility group (HMG) domain transcription factor Sox2 has been shown in 
vitro, using SC/dorsal root ganglion (SC/DRG) co-cultures and adenoviral over-
expression of Sox2 in SCs, to inhibit the induction of Krox20 and myelination of 
axons (Le et al., 2005a), but a demonstration of the potential inhibitory role of Sox2 
in vivo within the intact peripheral nerve has not yet been provided.  
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In order to test the role of Sox2 in vivo, we have made use of a conditional 
Sox2IRESGFP allele (Lu et al., 2010), which is activated in a cell-specific manner by 
crossing with the SC-specific P0-CRE line, and have tested the effects of ongoing 
Sox2 expression upon PNS myelination and repair. These experiments show, for the 
first time, that Sox2 in vivo will suppress PNS myelination and re-myelination 
following injury. In addition, persistent Sox2 expression in the adult nerve is sufficient 
to induce SC proliferation and an ongoing inflammatory state within the intact 
peripheral nerve.  
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Materials and Methods 
Reagents 
Adenoviruses expressing Krox20/GFP, Sox2/GFP and GFP control were previously 
described (Le et al., 2005b, Nagarajan et al., 2001, Parkinson et al., 2004a, 
Parkinson et al., 2008b). Antibodies against Sox2 were from Novus Biological (NB 
110-37235SS) for western blotting and Millipore (AB5603) for immunostaining. 
Antibodies against myelin basic protein (MBP) (sc-13912),β2A Tubulin (sc-134229) 
and alpha6 integrin (F6) were from Santa Cruz Biotechnology (Wembley, UK).  
Antibodies to N-Cadherin (610920), -catenin (610163) and cJun (610327) were 
from Becton-Dickinson (Oxford, UK). Antibody to Ki67 (Ab15580) was from Abcam 
(Cambridge, UK) and Krox20 (PRB-236P) from Covance (Cambridge, UK). Antibody 
to Sox10 was from Abcam (Ab155279) and laminin alpha2 antibody (ALX-804-190) 
from Enzo (Exeter, UK) Antibodies against myelin protein zero (P0) and periaxin 
were as described (Archelos et al., 1993, Gillespie et al., 1994). Biotinylated 
antibodies, Alexafluor fluorescently conjugated antibodies and fluorescently 
conjugated streptavidin were as previously described (Doddrell et al., 2013b). 
Transgenic mice and genotyping 
Transgenic mouse breeding and experiments were carried out according to Home 
Office regulations under the UK Animals (Scientific Procedures) Act 1986. Ethical 
approval for experiments was granted by Plymouth University Animal Welfare and 
Ethical Review Board. To identify effects of Sox2 over-expression in SCs in vivo, we 
crossed homozygous Rosa26R-Sox2IRESGFP mice (Lu et al., 2010) with P0-CRE 
(mP0-TOTACRE) mice (Feltri et al., 1999).  This generated heterozygous Rosa26 
Sox2IRESGFP CRE positive (+) and CRE negative (-) offspring. Heterozygous 
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Rosa26 Sox2IRESGFP CRE+ animals were then backcrossed with homozygous 
Rosa26 Sox2IRESGFP CRE– mice to generate heterozygous and homozygous 
Rosa26R-Sox2IRESGFP CRE– and CRE+ mice.  CRE+ animals carrying one copy of 
the Rosa26 Sox2IRESGFP transgene are referred to as Sox2HetOE; CRE+ animals 
carrying two copies of the Rosa26 Sox2IRESGFP transgene as Sox2HomoOE mice. 
For analysis of both Sox2HetOE and Sox2HomoOE mice, age and sex-matched CRE- 
animals of the same Rosa26 Sox2IRESGFP transgene status are used as controls. 
For mouse genotyping, genomic DNA was extracted using the HotSHOT method 
and analysed as previously described (Lu et al., 2010, Feltri et al., 1999, Truett et al., 
2000). 
 
Nerve Injury 
For nerve crush injury, the right sciatic nerve was compressed using a pair of round 
end forceps, as previously described (Dun and Parkinson, 2015). The left sciatic 
nerve was left uninjured. Mice were euthanized at the indicated time and both the 
uninjured contralateral and injured distal sciatic nerves collected for analysis.  
 
Cell culture and adenoviral infection 
Rat SCs were prepared from postnatal day 3 rats, as previously described (Brockes 
et al., 1979, Parkinson et al., 2001). SCs were infected with GFP/Krox-20 (GFP/K20) 
(Parkinson et al., 2004a, Nagarajan et al., 2001), control GFP or GFP/ Sox2 
adenovirus (Le et al., 2005b) or both GFP/Sox2 and GFP/K20 (Sox2/K20) 
adenovirus for 24 hours (h) in defined medium (DM) (Jessen et al., 1994) then 
incubated for a further 24h in DM before fixing and immunolabelling.  
8 
 
 
Immunocytochemistry, immunohistochemistry and western blotting 
SCs were cultured on poly L-lysine/laminin coated glass coverslips as previously 
described (Jessen et al., 1994). For immunohistochemical analysis of nerve sections, 
nerves were fixed in 4% w/v paraformaldehyde and embedded for cutting of 
cryosections. All staining, antibodies, counts and confocal and fluorescence 
microscopy were as previously described (Doddrell et al., 2013a, Parkinson et al., 
2008a, Parkinson et al., 2003b). Anti-MBP (1:100) and anti-Ki67 (1:200) antibodies 
were diluted in antibody diluting solution (ADS) with 0.2% Triton X-100 and 
incubated overnight at 4ºC. For western blotting, nerve samples were lysed in SDS 
buffer and protein electrophoresed on SDS-polyacrylamide gels. (Doddrell et al., 
2013b, Parkinson et al., 2004a, Parkinson et al., 2008b, Parkinson et al., 2003a). 
β2A Tubulin was used as loading control for western blots. 
 
Transmission electron microscopy (TEM) 
Nerves were fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer pH 7.2, post-
fixed in 1% osmium tetroxide, dehydrated and embedded in resin. Semi-thin 
sections were cut using a glass knife and stained with toluidine blue. Ultra-thin 
sections were cut and stained with uranyl acetate and lead citrate. Sections were 
photographed and examined using a JEOL 1200EX, or 1400 TEM microscope. For 
quantification of G ratio in intact and injured nerves, axon diameter and fibre (axon 
+ myelin) diameter was measured from 200 axons from each animal using Image J, 
which allowed for myelin thickness and G-ratio calculation. For quantification of 
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numbers of myelinated/degenerated fibres per field, average counts were made 
from 5 separate fields from both P60 control and Sox2HomoOE nerves. 
 
Functional testing  
Motor capacity in 6 and 8 week old mice was assessed by rotarod analysis. Rotarod 
training and final testing was as previously described (Saporta et al., 2012b, Kuhn et 
al., 1995). For these tests, the rod accelerated from 2 to 30 rotations per minute over 
a time period of 250 seconds.  
For measurements of nerve conduction velocity (NCV), sciatic nerves from P21 or 
P90 animals were dissected and placed into a perfusion chamber for 30-45 minutes 
before measurements were initiated. During this time the sciatic nerves were 
incubated at 37ºC, and perfused with artificial cerebrospinal fluid (aCSF) as 
previously described (Fern et al., 1998, Alix and Fern, 2009).  The distal end of the 
sciatic nerve were positioned within an aCSF filled glass stimulating electrode and 
compound action potentials (CAP) induced as previously described (Alix and Fern, 
2009). CAPs were recorded by the second recording aCSF filled glass electrode 
surrounding the proximal end of the sciatic nerve (Fern et al., 1998) and  displayed 
using Signal software (Cambridge Electronic Design).  NCVs were calculated using 
two parameters: (1) the length of the stimulated nerve, and (2) the time difference 
between the start of the stimulus artefact to the peak of the CAP.  
Functional recovery was measured on mice following injury using the static sciatic 
index (SSI) measurement. Paw print measurements were taken using a video 
camera from each mouse before surgery (0 days) and up to 21 days following injury 
to calculate the SSI (Baptista et al., 2007).  
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Statistics 
For all experiments n=3 unless otherwise stated. All graphs display the arithmetic 
mean with error bars representing one standard error of the mean. Statistical 
analysis was carried out using a student t-test and p-value used to denote 
significance. Significance was calculated between control and test groups and 
denoted on figures as:  * p< 0.05, ** p< 0.01 and ***p<0.005. 
Due to small sample sizes (n<5 for most comparisons), assumptions of how well 
normality and equal variances fit data could not be reliably assessed. Sample size 
was not predetermined by statistical methods and randomisation not applied. For 
functional testing by SSI, the evaluation was made by an individual blinded to the 
animal genotype. No samples or data were excluded from the analysis. The n 
number for each experiment is stated in the appropriate Figure legend.  
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Results 
 
Sox2 blocks Krox20-driven expression of myelin-associated proteins. 
 
The analysis of mice with a hypomorphic allele of Krox20/Egr2 (Egr2Lo/Lo) showed 
both PNS hypomyelination and continued post-natal expression of the Sox2 
transcription factor in SCs (Le et al., 2005a). This study also showed that high levels 
of Sox2 in SCs blocked the in vitro induction of Krox20 by cyclic AMP and 
myelination in SC/DRG co-cultures. Previous analysis of inhibitors of myelination, for 
example the cJun transcription factor, have shown that, cJun can both inhibit the 
induction of Krox20 in SCs as well as preventing the activity of exogenously 
expressed Krox20 to induce myelinating SC markers. In this way, cJun acts as an 
inhibitor of myelination both upstream and downstream of Krox20 function 
(Parkinson et al., 2004b). While Sox2 has been shown to block Krox20 induction in 
SCs by cyclic AMP (Le et al., 2005a) we tested whether maintained Sox2 can also 
inhibit the action of the pro-myelinating transcription factor Krox20 to induce 
myelinating SC markers (Parkinson et al., 2004b). In adenoviral co-infection 
experiments, as expected, Krox20 induced both the expression of myelin protein 
zero (P0) and the myelinating cell marker periaxin in SCs (Parkinson et al., 2003b, 
Parkinson et al., 2004b). Co-expression of Sox2 with Krox20 in SCs showed that 
Sox2 strongly antagonised Krox20-induced expression of both P0 and periaxin (Fig. 
1 A-H, I), confirming, in vitro, that maintained Sox2 expression can block the 
myelination programme both upstream and downstream of Krox20 induction in SCs. 
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Sox2 expression inhibits myelination in vivo. 
 
We next tested whether Sox2 can act as an inhibitor of myelination in vivo within the 
intact nerve. A conditional over-expressing allele for Sox2 (Sox2IRESGFP), inserted 
into the Rosa26 locus, has been previously described that upon CRE-mediated 
recombination will express both Sox2 and enhanced green fluorescent protein (GFP) 
(Lu et al., 2010). In order to drive SC-specific expression of Sox2, we used the well 
characterised mP0TOTA-CRE (P0-CRE) line (Feltri et al., 1999) to remove the floxed 
‘stop-cassette’ sequence and allow cell-specific expression of Sox2 and GFP in SCs. 
We have characterised nerves from transgenic CRE+ mice that have either one 
(Sox2HetOE) or both (Sox2HomoOE) recombinant Rosa26-Sox2IRESGFP alleles and the 
effects of Sox2 expression upon PNS myelination and repair.  
 
We first analysed sciatic nerves of mice carrying one copy of the Sox2IRESGFP 
transgene. Rosa26 wild-type/Sox2IRESGFP/CRE+ mice (Sox2HetOE) showed both 
Sox2 and GFP expression in the SCs of the nerve. Sox2 expression in control and 
Sox2HetOE nerves was confirmed by western blot and immunolabelling (Fig. 2I, J and 
Fig. S1 A-D). These nerves and controls were analysed at postnatal day (P) 7 and 
P21 time points by transmission electron microscopy (TEM) (Fig. 2A-D). While there 
is no apparent defect at this stage in axonal sorting, SCs appear to make a normal 
1:1 relationship with the axons, there is a substantial reduction in myelin thickness at 
P7 (Fig. 2 B, E) and at P21 (Fig. 2 D, G), resulting in an increased average G-ratio 
(0.71±0.003) for Sox2HetOE compared to 0.68±0.002 for control at P21. Western 
blotting of sciatic nerve from control and Sox2HetOE at both P3 and P7 showed 
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decreases in Krox20 and the myelin proteins P0 and myelin basic protein (MBP, Fig. 
2I). We also observed significant increases in the numbers of un-myelinated axons 
at both P7 and P21 in Sox2HetOE nerves compared to controls (Fig. 2 F, H). 
 
Analysing Sox2HetOE animals at later timepoints, we observed that the myelination in 
the PNS appeared to return to normal. At P60 there was no significant difference in 
G-ratio compared to control animals (0.65±0.02 for Sox2HetOE compared to 0.66±0.02 
for controls), nerve morphology of Sox2HetOE  nerves was completely normal at P60 
(Fig. 3 L and Fig. S1 J-L) and electrophysiology of Sox2HetOE  nerves showed no 
changes in nerve conduction velocity at P90 compared to control nerves (Fig. S1 I). 
We analysed expression of the Sox2IRESGFP transgene in these Sox2HetOE animals 
and found that the expression of both Sox2 and GFP was high at P7 but declined 
from P21 onwards and were both undetectable at later timepoints, either by western 
blot or by immunocytochemistry (Fig. 2 J and Fig. S1 A-H) ). We were unable to 
discern why expression levels of Sox2 and GFP decline in these Sox2HetOE mice, but 
it does show that loss of Sox2 over-expression in a hypomyelinated nerve from P21 
onwards will allow myelination to proceed and apparently complete normally by P60 
in the mouse PNS.  
 
Next, we performed crosses to generate animals carrying two copies of the 
Sox2IRESGFP transgene and examined whether in this case Sox2 expression 
persisted in the nerve in CRE+ (Sox2HomoOE) animals and the effects of such 
expression. Sox2HomoOE animals showed a similar hypomyelinating phenotype with 
ongoing Sox2 expression at P7, P14 and P21 timepoints in CRE+ animals and Sox2 
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continued to be expressed up to P60, as measured by either immunolabelling or 
western blot (Fig. 3 A-H, K and data not shown). 
P60 adult Sox2HomoOE animals were smaller in size compared to controls and showed 
a typical hindlimb clasping when lifted by the tail (Fig. 3 N-P), indicating a possible 
reduction of PNS myelination. TEM analysis of P60 Sox2HomoOE nerves showed 
hypomyelination within the adult nerve (Fig. 3 I, J), showing that ongoing Sox2 
expression will effectively inhibit myelination even at this later timepoint in vivo. 
Immunocytochemistry and western blotting of Sox2HomoOE nerves at both P7 and P60 
showed reduced levels of Krox20 and of the myelin proteins P0 and MBP (Fig. 3 K 
and Fig. S2 A-F, I). Levels of the Sox10 transcription factor protein, a key driver of 
myelination (Finzsch et al., 2010, Frob et al., 2012)  were unchanged at P7, but 
actually increased in Sox2HomoOE nerves at P60 (Fig. S2 G), presumably due to 
increased numbers of SCs within the nerve. (see below and Fig. 7). Corresponding 
to the reduction in myelin protein expression, a significant increase in the G-ratio and 
numbers of unmyelinated axons was observed in Sox2HomoOE nerves at P60 
compared to control and Sox2HetOE animals (Fig. 3 L, M).  
 
More detailed examination of P7 and P60 Sox2HomoOE nerves showed a number of 
additional effects of Sox2 expression upon nerve morphology. At P7, although SCs 
are making a 1:1 relationship with axons, there is a stalling of the ensheathment (Fig. 
4 A, B). Also at this age, where myelination is observed, we see an apparent lack of 
compaction in the outer myelin membrane layers of the SCs (Fig. 4 D, E). At P60, 
semi-thin and cryostat sections of Sox2HomoOE nerves show reduced myelination, but 
also some evidence of both axonal loss and ongoing myelin breakdown (Fig. 4 F, G, 
Q-T). Additionally at P60 we saw highly disorganised Remak bundles within the 
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Sox2HomoOE nerves, with groups of small diameter axons not separated by SC 
cytoplasm, in contrast to control nerves, and observed SCs extending abnormal 
processes and engulfing collagen fibres (Fig. 4 H-L). An examination of basal lamina 
structure in P60 Sox2HomoOE nerves with 6 integrin and laminin 2 staining showed 
an abnormal and diffuse staining pattern in Sox2HomoOE nerves as compared to 
controls (Fig. 4 M-P).  
Similar SC behaviour was observed using in vitro SC/DRG myelinating co-cultures 
with Sox2-overexpressing SCs; 21 days after ascorbic acid addition to trigger 
myelination, Sox2 overexpressing SCs did not associate correctly with axons, 
produced many cellular processes and produced very little myelin as compared to 
controls (Fig. S3). 
Sox2 over-expression reduces nerve conduction velocity (NCV), motor 
function and sensory function. 
 
Following on from the molecular characterisation of nerves over-expressing Sox2, 
we next compared the NCV in control and Sox2HetOE animals. Analysis of compound 
action potentials in revealed that Sox2HetOE  nerves have significantly decreased 
NCVs  compared to control nerves at P21 (Fig. 5 A; see Fig. S4C for original 
electrophysiological recordings), although this had corrected by P90 (Fig. S1 I), 
consistent with the normal myelination at this timepoint in these animals (Fig S1 J-L). 
Next, motor functional analysis was tested using a rotarod with an increasing speed 
and recording the latency to fall (Saporta et al., 2012b, Wrabetz et al., 2006). A 
significantly reduced latency was observed in Sox2HomoOE mice at both 6 weeks and 
8 weeks of age.  Although not significant, a slight reduction in latency was also 
observed in Sox2HetOE mice at 6 weeks and 8 weeks of age (Fig. 5 B, C).  
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Further analysis of sensory function was carried out using toe pinch (pressure) and 
Von Frey filament (light touch) testing. At 6 weeks of age, toe pinch testing showed a 
reduction in the ability of Sox2HomoOE mice to response to pressure stimuli, compared 
to control and Sox2HetOE mice (Fig. S4 A). In testing using Von Frey filaments, we 
found that Sox2HomoOE mice also had a significantly decreased ability to respond to 
light touch stimuli compared to control mice (Fig. S4 B). 
 
Increased levels of immature SC markers N-Cadherin and cJun in adult 
Sox2HomoOE nerves. 
 
N-cadherin is expressed in the developing nerve and declines during myelination 
with a reciprocal up-regulation of E-cadherin, but is re-expressed following nerve 
injury (Crawford et al., 2008, Wanner et al., 2006). Expression of Sox2 in SCs has 
been shown to drive re-localisation of N-cadherin, a cell surface adhesion molecule, 
and allow SC clustering in the nerve bridge following PNS injury (Parrinello et al., 
2010a). Such clustering is effected by the formation of adherens junctions through a 
calcium-dependent homophilic cadherin-cadherin interaction between SCs (Wanner 
and Wood, 2002). Immunolabelling of P60 sciatic nerve sections showed a clear 
increase in N-cadherin levels in SCs from Sox2HomoOE nerves compared to controls 
with an apparent cell membrane localisation (Fig. 6 A-D). Western blotting confirmed 
an increase in N-cadherin levels in Sox2HomoOE nerves as well as increased levels of 
the cJun transcription factor, a marker of promyelinating SCs (Parkinson et al., 
2004b) (Fig. 6 I, J). 
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-catenin is a binding partner of N-Cadherin and has been shown to both co-localise 
at the SC-axon interface to regulate SC polarity (Lewallen et al., 2011) and to 
positively regulate SC proliferation in SC-DRG co-cultures (Gess et al., 2008). -
catenin immunolabelling showed slightly raised levels of expression in P60 
Sox2HomoOE nerves in vivo (Fig. 6 E-I). Corresponding in vitro experiments with rat 
SCs showed that enforced Sox2 expression alters SC morphology (Fig. S5 A, B), 
localises both N-cadherin and -catenin to the SC membrane in a calcium-
dependent manner (Fig. S5 C-J) and increased the levels of both proteins (Fig. S5 
K); interestingly, expression of a 4-hydroxytamoxifen-regulatable Sox2 (Sox2-ERTM) 
protein in 3T3 fibroblasts was also sufficient to drive upregulation and membrane 
localisation of the N-Cadherin protein following tamoxifen addition in this 
heterologous cell type (Fig. S6 A-E). 
SC proliferation is increased by Sox2 expression in vivo. 
 
In Sox2HomoOE mice we saw increased numbers of SCs within the nerve at ages from 
P7 onwards (Fig. 7 G, H and Fig. S7 F-M). To identify whether Sox2 increased SC 
proliferation in vivo, we immunolabelled P7 and P60 nerve sections with Ki67. The 
number of GFP/Ki67 positive nuclei was significantly increased in Sox2HomoOE mice at 
both P7 and P60 (Fig. 7 A-F, I, J), however no significant increase in Ki67 staining or 
nuclei number was detected at time points as early as P3 (Fig. S7 A-E and data not 
shown).  
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Increased numbers of macrophages in uninjured Sox2-overexpressing nerves.  
Having observed that increased Sox2 expression maintains SCs in a proliferative 
non-myelinating state in the adult nerve, and also some myelin breakdown and 
axonal degeneration, we next tested whether this was associated with any increase 
in macrophages and other immune cells within the intact nerve. By double labelling 
for Iba1 and F4/80, we checked macrophage numbers in P7, P21 and P60 control 
and Sox2HomoOE nerves and found a significant increase in the number of 
macrophages within these intact Sox2HomoOE nerves at both P21 and P60 (Fig. 8 A-
G).  An increase, although not significant, was also found in the numbers of CD3 
positive T-cells in intact P60 Sox2HomoOE nerves compared to controls (Fig. S8). 
 
Sox2 over-expression impairs SC remyelination and functional recovery 
following nerve injury. 
 
Although Sox2 re-expression has been shown to drive cell sorting in the nerve bridge 
following transection injury (Parrinello et al., 2010b), it is not known how maintained 
Sox2 expression in SCs will affect nerve repair and regeneration in the distal nerve 
following a crush injury. Thus, we next investigated the effect of maintained Sox2 
expression on SC re-myelination for up to 21 days post crush injury (21DPI). As 
Sox2HomoOE animals show profound hypomyelination even at P60 we used Sox2HetOE 
animals for these experiments. As described above, in Sox2HetOE mice, Sox2 and 
GFP expression begins to decline at P21 and myelination corrects with a normal 
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nerve morphology and G-ratios at P60 as well as an unchanged nerve conduction 
velocity at P90 in these animals (above and Fig. S1 I-L). 
As we observe transgene expression of both Sox2 and GFP at early developmental 
timepoints in the Sox2HetOE animals, we hypothesized that following PNS injury the 
accompanying de-differentiation of SCs distal to the injury site may be sufficient to 
cause re-activation of transgenic Sox2 and GFP expression in the Sox2HetOE animals, 
allowing us to study effects of ongoing Sox2 expression in a repairing nerve. This 
idea was proved correct and western blot and immunolabelling showed higher levels 
of Sox2 induction in Sox2HetOE animals compared to controls at 7 days post-crush 
injury (DPI) and that Sox2 and GFP expression were maintained at 21 DPI in these 
animals compared to controls (Fig. 9 A-F and L, M).  Using TEM, we evaluated SC 
re-myelination by analysing distal nerve sections from control and Sox2HetOE mice at 
21DPI.  Sox2HetOE sciatic nerves distal to the site of injury were hypomyelinated (Fig. 
9 G, H), with a significantly increased average G-ratio of 0.86±0.028 compared to 
control nerves, which had an average G-ratio of 0.69±0.028 at this timepoint (Fig. 9 I; 
see Fig. S9 A for G-ratio scatter plot). A significant increase in the percentage of 
unmyelinated axons and decrease in P0 protein expression were observed in 
Sox2HetOE mouse nerves at 21DPI (Fig. 9 J, M).  
Whilst numbers of regenerated axons were apparently unchanged, as visualised by 
neurofilament staining, further analysis of regenerated nerves at 21DPI did show a 
significant increase of axonal diameter in the repaired nerves of Sox2HetOE animals 
as compared to controls (Fig. S9 B), as well as significantly increased numbers of 
macrophages still present within the nerve at this timepoint (Fig. S9 C-G). No 
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significant difference in macrophage numbers was observed between uninjured 
nerves from control and Sox2HetOE animals (Fig. S9 G).  
Having observed that Sox2 over-expression post-injury leads to a marked reduction 
in SC re-myelination in Sox2HetOE mice following injury, we next tested the functional 
recovery of these animals.  Tests of functional recovery using an SSI measurement 
showed that recovery in Sox2HetOE   mice was significantly reduced up to 21DPI 
compared to control mice (Fig. 9 K). This experiment validated that in addition to 
impairing remyelination, prolonged Sox2 expression in SCs following injury also 
attenuates functional recovery in these animals. 
We next quantified re-myelination by analysing myelin protein re-expression 
following sciatic nerve injury. Corresponding to the TEM analysis (Fig. 9 G, H), 
western blotting confirmed that continued expression of Sox2 in the SCs of Sox2HetOE 
nerves following injury reduced the re-expression of P0 at 21 DPI in the distal nerve 
(Fig. 9 L, M).  Analysis of SC proliferation in the Sox2HetOE mice at 21 DPI also 
showed an ongoing and significantly increased proliferation in the nerve even at this 
timepoint after injury (Fig. 9 N), once more showing the potential for Sox2 to maintain 
SCs in an undifferentiated and proliferative state in vivo within the nerve.  
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Discussion 
 
Within SCs, the onset of myelination is controlled by a network of transcription 
factors that co-operate to ensure a timely and appropriate ensheathment and 
myelination of axons (Svaren and Meijer, 2008). Mutations in many of these factors, 
such as those in the zinc finger protein Krox20 (Egr2), cause hypomyelinating 
neuropathies in both human patients and rodent models (Funalot et al., 2012, Baloh 
et al., 2009, Desmazieres et al., 2008, Arthur-Farraj et al., 2006, Warner et al., 1999, 
Warner et al., 1998). 
Although there are a number of positive transcriptional regulators of myelination in 
SCs such as Krox20, Sox10, NFATc4 and Oct6, an increasing number of negative 
regulators of myelination such as MAP kinase signalling through p38 and ERK1/2 
pathways, Notch signalling and the transcription factors Pax3 and cJun have been 
shown to block the myelination of SCs (Doddrell et al., 2012, Harrisingh et al., 2004a, 
Woodhoo et al., 2009a, Napoli et al., 2012, Yang et al., 2012, Parkinson et al., 2004b, 
Parkinson et al., 2008a).  
The initial description of Sox2 as an inhibitor of PNS myelination came from the 
finding that mice with a hypomorphic Krox20 (Egr2) allele (Egr2Lo/Lo), and thus 
reduced Krox20 expression, showed hypomyelination and increased expression of 
Sox2 in SCs.  Further experiments, which aimed to determine the function of Sox2 
as a negative regulator of myelination have used a virally-mediated expression 
system in vitro. These experiments showed that over-expression of Sox2 in vitro 
prevents both the induction of myelinating SC markers such as Krox20 and P0 and 
enhanced the proliferation of SCs to the mitogen neuregulin (Le et al., 2005b). Whilst 
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this gives a good indication of Sox2 function, however, as assays of myelination in 
vitro may not fully reflect the situation in vivo (Lewallen et al., 2011, Golan et al., 
2013),  thus the aim of this study was  to fully characterise the effects of maintained 
Sox2 expression upon both myelination and functional repair within the intact nerves 
of the PNS in vivo. In addition, this in vivo approach allows us to measure effects of 
maintained Sox2 expression in SCs upon immune cell influx into the nerve, both 
following injury and in the intact nerve.   
Our experiments show a strong inhibitory effect of Sox2 on the myelination 
programme of SCs at all timepoints examined. The expression of myelinating SC 
markers such as Krox20, myelin basic protein and P0 are all reduced and 
morphological analysis shows a severe hypomyelination of post-natal nerves. 
Correspondingly, an analysis of SC-specific Sox2 nulls has shown a slight 
acceleration of early post-natal myelination (MDA and X-PD, unpublished 
observations), confirming the inhibitory role of Sox2 in controlling developmental 
myelination. However, in contrast to experiments with SC-specific cJun and 
p38alpha MAP kinase nulls (Parkinson et al., 2008a, Roberts et al., 2016), we do not 
observe a function for Sox2 in the down-regulation of myelin proteins following injury. 
Injury experiments in Sox2 null nerves showed a similar profile of myelin protein loss 
compared to controls (X-PD, unpublished observations). Thus the role of Sox2 
appears to be more important in regulating the onset of myelination both during 
development and following injury rather than in the events of SC dedifferentiation 
following axotomy. 
An analysis of other potential Sox2 targets showed, both in vitro and in vivo, that 
Sox2 decreased mRNA and protein levels of the nectin-like protein Necl4 (also 
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known as Cadm4) in SCs (Fig. S10). Inhibition of Necl4 function in SCs, either by 
shRNA knockdown or expression of a dominant negative form of the protein, 
prevents normal SC-axon interaction, Krox20 induction and myelination in vitro 
(Maurel et al., 2007, Golan et al., 2013, Spiegel et al., 2007), but loss of Necl4 in vivo 
is associated with focal hypermyelination and a phenotype resembling several CMT 
subtypes (Golan et al., 2013); it is therefore unclear at present what role, if any, 
decreased Necl4 levels may play in the phenotype we observe in our Sox2 over-
expressing animals.  
Over-expression of the mammalian Lin28 homologue B (Lin28B) RNA binding 
protein and reduction of levels of the let-7 family of microRNAs in SCs has been 
shown to inhibit peripheral nerve myelination in vivo (Gokbuget et al., 2015). As 
Sox2 has been shown to increase Lin28B levels in embryonic stem cells and neural 
progenitors (Cimadamore et al., 2013, Marson et al., 2008), we measured Lin28B 
protein levels in control and Sox2HomoOE nerves at P60.  We do not detect Lin28B 
expression in either control or Sox2HomoOE adult nerve (Fig. S2 H), therefore 
seemingly eliminating the Lin28B/let-7 signalling axis as mediating the Sox2-induced 
hypomyelination. 
 It is still unclear as to why the expression of the Sox2IRESGFP transgene 
declines in the Sox2HetOE animals up to P21, as the construct is inserted into the 
Rosa26 locus and the construct also contains a synthetic cytomegalovirus early 
enhancer / chicken beta actin (CAG) promoter (Lu et al., 2010), but these issues of 
silencing of the transgene expression were not seen in the Sox2HomoOE animals, 
allowing us to monitor the effects of Sox2 expression up to P60 in these animals. 
Analysis of Sox2HetOE nerves up to P60 allowed us to measure the effects of the 
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removal of Sox2 over-expression in SCs from P21 onwards. In this case the nerves 
continued their myelination and by P60 they appeared normally myelinated with G-
ratios similar to control nerves, once again underlining a remarkable ability of SCs 
within the nerve to resume and complete their myelination programme.  
The normal myelination observed in P60 Sox2HetOE nerves and re-activation of 
Sox2 expression following injury  in these animals also allowed us to confirm that 
Sox2 negatively regulates both developmental myelination and re-myelination 
following injury, in contrast to some regulators within SCs that have developmental 
or repair-specific functions (Arthur-Farraj et al., 2012, Fontana et al., 2012, Kim et al., 
2000, Jessen and Mirsky, 2016, Mindos et al., 2017). 
Whether negative regulators of myelination play roles in the pathology of 
human peripheral neuropathies or mouse models of these conditions has been 
recently examined. Increased expression of the cJun transcription factor in SCs has 
been observed in both patients with Charcot-Marie-Tooth (CMT) disease, chronic 
inflammatory demyelinating polyradiculopathy and mouse models of CMT (Saporta 
et al., 2012a, Hutton et al., 2011, Hantke et al., 2014, Klein et al., 2014), and 
although it has been suggested that abnormal expression of cJun may be involved in 
the pathology of the hypomyelination seen (Saporta et al., 2012a), recent work using 
the C3 mouse model of CMT1A showed that cJun expression was actually protective. 
Genetic removal of cJun in the C3 mouse, which models human CMT1A, led to a 
progressive loss of myelinated sensory axons and increasing sensory-motor loss 
(Hantke et al., 2014). Thus, as opposed to driving the neuropathy in these animals, 
raised expression of cJun in SCs is a protective mechanism to ameliorate the 
disease state. Recent reports have shown that levels of Sox2 mRNA are elevated in 
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in mouse models of CMT types 1A and 1B (D'Antonio et al., 2013, Giambonini-
Brugnoli et al., 2005), but any potential roles for this increased expression are 
currently unknown. 
The finding of increased macrophage numbers within both the intact Sox2HomoOE 
nerve at P60 and within the Sox2HetOE nerve following injury suggests a role for Sox2 
in the control of macrophage entry to the nerve, although it is not clear whether this 
is a direct effect or is due to the lack of myelination or the apparent ongoing myelin 
breakdown and axonal loss seen in the adult P60 Sox2HomoOE nerves (Fig. 4 F, G).  
In conclusion, we have identified that Sox2 acts as an in vivo inhibitor of the 
myelinating phenotype of SCs and have shown new roles for this protein in both 
controlling the proliferation of SCs and recruitment of macrophages to the nerve. 
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Figures and Figure legends: 
Figure 1. 
 
Figure 1:  Sox2 antagonises Krox20 induced myelin protein expression in vitro.  
A-H.  Immunofluorescence of rat SCs infected with GFP/Krox20 (A, B, E, F) or 
Sox2/Krox20 (C, D, G, H) expressing adenovirus, showing inhibition of Krox20-
driven periaxin (C, D) and P0 expression (G, H) by Sox2. Hoechst stain (Ho) is used 
to reveal SC nuclei. Scale bars 20m. M. Graph showing the percentage of periaxin 
and P0 positive cells, in GFP/K20 and Sox2/K20 adenoviral infected SCs.  
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Figure 2. 
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Figure 2:  Inhibition of myelination in Sox2 over-expressing mice in vivo. A–D. 
TEM of sciatic nerves from control post-natal day (P) 7 control (A) and Sox2HetOE 
mice (B) and P21 control (C) and Sox2HetOE mice (D).  Scale bar A-D 5 m.   E. 
Graph illustrating distribution of myelin thickness in control and Sox2HetOE mouse 
nerves. F. Graph showing a significant increase in the proportion of unmyelinated 
axons above 1m diameter in the sciatic nerves of P7 Sox2HetOE mice compared to 
control mice.  G. Graph showing the distribution of G-ratio of axons in P21 control 
and Sox2HetOE nerves. H. Graph showing a significant increase in the population of 
unmyelinated axons above 1m diameter in the sciatic nerves of P21 Sox2HetOE mice 
compared to control mice. I. Western blots showing the reduction in Krox20, P0 and 
myelin basic protein (MBP) proteins in P3 and P7 control and Sox2HetOE nerves. J. 
Western blots showing Sox2 and GFP expression in post-natal control and Sox2HetOE 
mice. 
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Figure 3. 
 
Figure 3: Analysis of Sox2 expression and myelination in Sox2HomoOE mice 
carrying two copies of the Sox2IRESGFP transgene. A-H. Immunohistochemical 
analysis of sciatic nerves stained with Sox2 antibody demonstrates that control 
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nerves do not express GFP or Sox2 at P7 (A, B) or P60 (C, D), whereas Sox2HomoOE 
nerves have high levels of GFP and Sox2 expression at both P7 (E, F) and P60 (G, 
H) ages. Scale bars 40m. I, J. TEM images of control (I) and Sox2HomoOE (J) nerves 
at P60. Scale Bar 5m. K. Western blots of control and Sox2HomoOE nerves at P7 and 
P60 showing a reduction in Krox20, P0 and MBP expression in vivo by Sox2 
expression in SCs. L, M. G-ratio measurements (L) and numbers of unmyelinated 
axons above 1m diameter (M) in control, Sox2HetOE and Sox2HomoOE nerves at P60. 
N. Sox2HomoOE mouse (black, on right side of picture) shows a reduced size at P60 
compared to control animals. O, P. Sox2HomoOE animals (P) show hind limb clasping 
when lifted by the tail, characteristic of peripheral hypomyelination, compared to a 
control littermate (O). 
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Figure 4. 
 
Figure 4: Morphology of P7 and P60 control and Sox2HomoOE nerves. A-E. P7 
sciatic nerves from control (C) and Sox2HomoOE animals (A, B, D and E). Whereas in 
control nerves SCs have formed proper myelin (C), in Sox2HomoOE nerves most SCs 
are stalled in the 1:1 stage (A, B). Where Sox2 over-expressing SCs do form myelin, 
they often show non-compaction of the outer myelin layers (white arrowheads in D 
and E).  Scale bars A, B: 500nm; C: 2m; D, E: 200nm. F, G. Semi-thin sections of 
P60 control (F) and Sox2HomoOE (G) nerves; arrows in G indicate possible axonal loss 
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and demyelination. Scale bar 20m. H-L. P60 control and Sox2HomoOE nerves. At P60 
most axons in Sox2HomoOE nerves are amyelinated and are surrounded by redundant 
SC basal lamina (black arrows in H and L) and several SCs show myelin debris in 
the cytoplasm (asterisks in I). Remak bundles, that in control nerves show proper SC 
cytoplasm separating axons (J), show bundles of axons touching each other (‘b’ in K 
and L) and aberrant SC processes (white arrow in L) whose basal lamina forms 
collagen pockets (white arrowheads in L). Scale bars H-L 1m. M-R P60 control and 
Sox2HomoOE nerve sections immunolabelled with 6 integrin (M, N), laminin 2 (O, P) 
and myelin basic protein (MBP)/GFP (Q, R). Scale bars 5m in M-P and 25m in Q, 
R. S, T.  Quantification of numbers of myelinated (S) and degenerating (T) fibres per 
field in P60 control and Sox2HomoOE nerves.  
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Figure 5. 
 
Figure 5: Nerve conduction velocity and motor function is reduced in Sox2 
over-expressing animals. A. Graph comparing the nerve conduction velocity (NCV) 
of sciatic nerves taken from control (n=11) and Sox2HetOE (n=13) mice at P21.  B, C. 
Graph showing the reduction in latency to fall using rotarod testing of control, 
Sox2HetOE and Sox2HomoOE mice at 6 weeks (B) and 8 weeks (C) of age. 6 weeks 
control n=7, Sox2HetOE n=4 and Sox2HomoOE n=6; 8 weeks control n=4, Sox2HetOE n=4 
and Sox2HomoOE n=6. 
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Figure 6. 
 
Figure 6: Expression and localisation of N-Cadherin and -catenin in P60 
Sox2HomoOE nerves. A-H. Immunolabelling of sciatic nerve sections from P60 control 
(A, B, E and F) and Sox2HomoOE (C, D, G and H) nerves showing localisation and 
levels of N-Cadherin (NCad, A-D) and -catenin (cat, E-H) in SCs. Sections are 
counterstained with Hoechst (Ho) to reveal nuclei. Scale bar 20m. I. Western blot 
showing elevated levels of Sox2, N-Cadherin and cJun in P60 Sox2HomoOE nerves as 
compared to controls. J. Quantification of western blots in panel I.  
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Figure 7. 
 
Figure 7: SC numbers and proliferation are increased in Sox2 over-expressing 
nerves. A-F. Sections of sciatic nerves taken from P7 control (A-C) and Sox2HomoOE 
(D-F) mice were immunolabelled with antibodies against Ki67. Scale bar 40m. 
Insets in panels D-F show higher magnification of Ki67/GFP positive SCs. G, H 
Graphs showing an increase in the number of SC nuclei in P7 (G) and P60 (H) 
Sox2HomoOE sciatic nerves compared to controls. Numbers given are total nuclei per 
sciatic nerve transverse section. I, J Graph showing a significant increase in the 
number of GFP/Ki67 positive nuclei in P7 (I) and P60 (J) Sox2HomoOE sciatic nerves 
compared to controls.  
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Figure 8. 
 
Figure 8: Increased numbers of macrophages in intact P60 Sox2HomoOE sciatic 
nerves.  Double immunolabelling of sciatic nerve sections from P60 control (A-C) 
and Sox2HomoOE (D-F) sciatic nerves with F4/80 and Iba1 to identify macrophages. 
Scale bar 40m. Insets in panels D-F show higher magnification of F4/80/Iba1 
double-positive macrophages within the nerve. G. Graphs showing quantification of 
macrophage numbers at P7, P21 and P60; a significant increase in macrophage 
numbers is observed in both P21 and P60 Sox2HomoOE nerves. 
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Figure 9. 
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Figure 9: Sustained Sox2 expression results in hypomyelination and reduced 
functional recovery following nerve injury. A-F Immunolabelling of distal sciatic 
nerves sections 21 days post-crush injury (DPI) with antibodies against Sox2, 
revealed that nerves from control animals no longer expressed Sox2 at this time 
point (A-C), whereas Sox2 (and GFP) levels remained elevated in the distal sciatic 
nerves of injured Sox2HetOE mice (D-F). Scale bar 40m. G, H. TEM pictures of distal 
sciatic nerve sections at 21 DPI revealed that axons in control nerves are 
remyelinated (G), whereas few axons appear to be remyelinated in Sox2HetOE nerves 
(H). Scale bar 5m I. G-ratio measurements revealed that Sox2HetOE sciatic nerves 
were significantly hypomyelinated compared to control nerves at 21 DPI. J. Graph 
showing a significant increase in the percentage of unmyelinated axons in Sox2HetOE 
nerves compared to control nerves at 21 DPI. K. Quantification of functional recovery 
by analysis of static sciatic index (SSI). Control n=5, Sox2HetOE n=7,  L. Western blot 
showing high levels of Sox2 at 21DPI leads to a reduction in P0 expression in 
Sox2HetOE mice. M. Quantification of western blots from panel L. N. Graph showing a 
significant increase in the number of Ki67 positive nuclei in distal Sox2HetOE sciatic 
nerves at 21 DPI compared to controls.  
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